	US 12,295,986 B2
	Combination immunotherapy for treatment of melanoma, colon or non-small cell lung cancers
Chensu Wang, Allston, MA (US); Karl Dane Wittrup, Boston, MA (US); and Darrell J. Irvine, Arlington, MA (US)
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Dec. 2, 2021, as Appl. No. 17/540,477.
Application 17/540,477 is a division of application No. 16/692,892, filed on Nov. 22, 2019, granted, now 11,235,032.
Claims priority of provisional application 62/796,013, filed on Jan. 23, 2019.
Prior Publication US 2022/0096601 A1, Mar. 31, 2022
Int. Cl. A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)

CPC A61K 38/2013 (2013.01) [A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55561 (2013.01)]

23 Claims

1. A method for treating a melanoma, colon cancer, and/or non-small cell lung cancer (NSLC) in a subject, comprising administering to the subject:

(a) priming dose comprising (i) interleukin (IL)-2, (ii) an immune checkpoint inhibitor polypeptide, (iii) a tumor targeting antibody or an integrin-binding polypeptide, and (iv) a cancer vaccine, wherein the priming dose induces or enhances an anti-tumor immune response in the subject; and

(b) at least one maintenance dose comprising an immune checkpoint inhibitor polypeptide, wherein the priming dose is administered at least four days prior to the at least one maintenance dose, thereby treating the melanoma, colon cancer, and/or NSLC in the subject.